Eyestem is a trailblazing cell therapy company led by a top-tier management team of clinical trials, cell therapy, and ophthalmology experts. Supported by a world-class advisory board and collaborations with industry pioneers, Eyestem is poised to make significant advancements in the field. Its lead candidate, Eyecyte-RPE, targets age-related macular degeneration and will soon enter human trials. With a long-term vision of democratizing access to cell therapy, Eyestem aims to develop a scalable platform capable of treating incurable diseases, transforming the healthcare landscape for the better.
The Hindu BusinessLine
February 25, 2024
Eyestem’s promising pipeline of products catches the eye of traditional pharma companies
Two pharmaceutical companies and a vaccine-maker invested in Eyestem (2022), putting the spotlight on the cell therapy company’s product pipeline. The six-year old company’s potential therapy for dry age-related macular degeneration, a global unmet medical need, awaits regulatory approvals in India for trial in humans, even as the company prepares to take the investigational new drug to Australia, says Eyestem co-founder and Chief Executive Jogin Desai.
August 22, 2023
Affordable gene and cell therapies need of the hour: Dr Kapil Bharti, Scientific Director, National Eye Institute
Eyestem Research, a pioneering cell therapy company, with a vision to democratize cutting-edge technologies for the bottom 99%, hosted India's first retinal cell and gene therapy conference.
October 31, 2022
Eyestem bags the Top Innovator award : ET Startup Awards 2022
It’s estimated that cell therapy products will cost more than $450,000 per injection globally. The Bengaluru-based Eyestem’s mission to democratise access to such treatment by bringing the cost down to less than a 50th of that won it the Top Innovator Award at the ET Startup Awards 2022.
Times of India
August 7, 2022
Eyestem raises Series A round from Biological E, Alkem and others
Eyestem, a Bengaluru-based cell therapy company, has raised $6.4 million (Rs 51 Crore) in a Series A round led by three pharma majors - Biological E. Limited (BE), Alkem, NATCO and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing investors Endiya Partners and Kotak Private Equity also participated in this round
March 23, 2022
Eyestem has a visionary approach to make cell therapy affordable in India
Eyestem's premier cell therapy solution to treat age-related macular degeneration or AMD, the leading cause for incurable blindness should be available in the market by 2024, heralding a new era of home-grown sophisticated frontier Lifesciences led solutions.
July 2, 2021
Eyestem is breaking cell therapy price barrier and its first target is an incurable eye disease
Bengaluru based Eyestem has set its sight on finding an affordable cure for an incurable eye disease – dry age-related macular degeneration (AMD) – the first of many conditions it wants to treat using a unique cell therapy platform.
The Hindu BusinessLine
May 26, 2021
Eyestem raises funds from Endiya Partners
This investment will enable Eyestem to reach their goal of becoming one of the first few companies in the world to develop a treatment for Dry Age-related Macular Degeneration (Dry AMD), the leading cause of incurable blindness affecting almost 170 million people – mostly above 50 years of age – across the globe.